CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making-Reference-Cited by-同舟云学术

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making

Published:2018-09-26 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Worst Thomas S.,Weis Cleo-Aron,Stöhr Robert,Bertz Simone,Eckstein Markus,Otto Wolfgang,Breyer Johannes,Hartmann Arndt,Bolenz Christian,Wirtz Ralph M.,Erben Philipp^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-32569-x.pdf

Reference47 articles.

1. Yafi, F. A. et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 108, 539–545 (2011).

2. Kojima, T., Kawai, K., Miyazaki, J. & Nishiyama, H. Biomarkers for precision medicine in bladder cancer. Int. J. Clin. Oncol. https://doi.org/10.1007/s10147-016-1068-8 (2016).

3. McConkey, D. J., Choi, W. & Dinney, C. P. N. Genetic subtypes of invasive bladder cancer. Curr. Opin. Urol. 25, 449–458 (2015).

4. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).

5. Mitra, A. P. & Lerner, S. P. Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. Urol. Clin. North Am. 42, 201–215, viii (2015).

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular biology, genetic, and epigenetics of bladder tumor;Genetics and Epigenetics of Genitourinary Diseases;2025

2. Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic Features;Cancer Research Communications;2024-09-01

3. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions;Clinical Lymphoma Myeloma and Leukemia;2024-07

4. CDKN2A copy number alteration in bladder cancer: Integrative analysis in patient-derived xenografts and cancer patients;Molecular Therapy: Oncology;2024-06

5. Characteristics of the Antitumor Effect of Doxorubicin and Pegylated Hyaluronidase on Models of Rat Brain Tumors;Bulletin of Experimental Biology and Medicine;2024-05